In this episode, Beatriz Grinsztejn, MD, PhD, discusses the data and recommendations for addressing social determinants as a strategy to support PrEP persistence and engagement for transgender women, including: HIV prevalence among transgender womenData on the PrEP cascade from the PrEParadas study of daily FTC/TDF among transgender womenData from the ImPrEP Study on early loss to follow-up, adherence, long-term engagement, and HIV incidence among transgender womenBarriers to PrEP uptake and adherence for transgender womenDrug–drug interactions between PrEP and feminizing hormone therapyIncreasing PrEP uptake and retention with peer health navigation for transgender womenFacultyBeatriz Grinsztejn, MD, PhDDirectorHIV/STI Clinical Research LaboratoryInstituto Nacional de Infectologia Evandro Chagas-FiocruzRio de Janeiro, BrazilIAS President-ElectLink to full program:https://bit.ly/3ZlICsL Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related